This research considers several features of value creation and value delivery (Lindgreen and Wynstra 2005) in the healthcare marketplace, with an emphasis on the complexity of creating and delivering value in a multiple stakeholder environment that includes both profit-oriented and not-for-profit motives. The drug market comprises the manufacture of products designed to treat consumers (profit motive) but also involves a key intermediary, namely, the physician (generally not-for-profit, with regard to pharmaceuticals). The relationships that constitute this marketplace include those between drug manufacturers and physicians, between physicians and consumers and, with the advent of direct-to-consumer (DTC) advertising of prescription drugs, between manufacturers and consumers.
Drug manufacturers, in their efforts to increase sales (and provide value to shareholders), attempt to create and deliver value to consumers by advertising directly to them. Manufacturers assert that such advertising increases consumers' healthcare knowledge, encourages dialogue with physicians and enhances the recognition and treatment of undiagnosed illnesses (Bonaccorso and Sturchio 2002; Mitka 2003) . This policy seems to garner support from end-user groups, at least in the United States and United Kingdom (Kucharsky 2005; Lowery 2003; Reast, Palihawadana and Shabbir 2008) . However, the approach has proven less popular among an important intermediary: physicians. Prior research that surveys physicians in New Zealand, the United States and United Kingdom indicates their general opposition to DTC advertising. If anything, physicians perceive that DTC advertising destroys rather than creates value (Mitka 2003; Thomaselli 2003; Yuan and Duckwitz 2002) . This study acknowledges these responses, as well as the ongoing calls for more research into how different value chain actors create and deliver value for customers (Lindgreen and Wystra, 2005) , and therefore provides a comparative investigation of DTC advertising across diverse cultures located in mainland Europe, the Middle East and Asia (Reast and Carson 2000; Reast, Palihawadana and Spickett-Jones 2004) .
In many countries, DTC advertising of prescription drugs is banned (Watson 2002) .
The initiation of such advertising in the United States in the early 1980s and in New Zealand in the 1990s prompted sustained ethical debates (Hensley and Vranica 2004; Lee, Salmon and Paek 2007) , as well as vast communications budgets. Drug brand owners were responsible for advertising expenditures of approximately $9.4 billion between 1996 (IMS Health, 2002 , and DTC advertising has contributed significantly to the struggling U.S. media market (Thomaselli 2006) . However, even in the U.S. market, calls for significant regulatory restrictions have followed the market withdrawals of high-profile DTC advertising power brands, such as Vioxx (Merck) and Bextra (Pfizer), due to alarming safety concerns (Edwards 2005) . The perceptions of overly aggressive DTC advertising strategies and the potential damage to corporate reputations (Wielondek 2005) have led some manufacturers to signal their intention to reduce their above-the-line expenditures (Arnold 2005 ). Yet despite these issues and criticisms, consumer support for DTC advertising appears resilient (Dolliver 2005; Kucharsky 2005) , with 70 percent of U.S. consumers claiming that they support a manufacturer's right to advertise directly to consumers.
Several variables may influence the likely international expansion of DTC advertising, such as increased calls for more drug information available to consumers, virtually unlimited international access to drug manufacturers' U.S.-targeted Web sites, increasing e-retailing of prescription drugs and lobbying by manufacturers (Rendon 2003) . Therefore, the introduction of DTC advertising is being actively considered in Canada (Kucharsky 2005) and Australia (Smith 2007) , and despite opposition to full DTC advertising in Europe (Watson 2002) , unbranded drug advertising is increasing in this market.
As an issue of major economic and ethical significance, DTC advertising has prompted extensive research, especially in U.S. and New Zealand markets. This research investigates both consumers' (Alperstein and Peyrot 1993; Pines 1998 ) and physicians' (Petroshius, Titus and Hatch 1995; Yuan and Duckwitz 2002) attitudes regarding the ethics (Hensley and Vranica 2004; Lee et al. 2007) , benefits (Desselle and Aparasu 2000) and issues (Mintzes et al. 2002; Prince 2003 ) associated with DTC practices. However, other than a few studies in Australia (Miller and Waller 2004) and the United Kingdom (Lowery 2003; Reast and Carson 2000; Reast et al. 2008; U.K. Consumers Association 2002) , little research notes responses by consumers or physicians to DTC advertising in the substantial drug markets of mainland Europe (which accounts for more than one-third of worldwide drug sales), the Middle East or the Far East.
The global healthcare market outside of the United States, New Zealand and the United Kingdom is vast, worth some US$167 billion in Europe, over US$7 billion in the Middle East and more than US$50 billion in South and East Asia (IMS, 2005) .
Furthermore, the three markets that have garnered existing research attention all are individualistic cultures (Hofstede 1991) , with relatively similar cultural profiles (see Appendix I). Considering the powerful influence of culture in many product and service domains (Yeniyurt and Townsend, 2003) , responses to DTC advertising seem likely to differ in countries whose cultural profile differs. Therefore, and considering possible bridgehead markets for the expansion of DTC advertising, we select three markets for further research. All three markets can classified as collectivist cultures, with low individualism scores and broadly similar cultural profiles (see Appendix I).
However, DTC advertising is not currently permitted in these three markets.
As one of the selected countries, Greece provides a representation of Hofstede's European Country profile and the cultural profile of Southern European countries, which also include Spain and Portugal (Hofstede 1991) . It contains one of the fastest growing healthcare markets in Europe and is the eighth largest of the 27 EU members.
We also select the United Arab Emirates as a representative of the Arab Countries noted by Hofstede (together with Egypt, Iraq, Kuwait, Lebanon, Libya and Saudi Arabia), because it reflects the cultural profiles within this region. The healthcare market growth rate in the United Arab Emirates is almost 8 percent, well above the regional average. Finally, the collectivist Taiwanese culture is highly representative of Hofstede's Asian Countries profile, broadly similar to mainland China and highly representative of other Asian countries such as Indonesia, South Korea and Thailand.
Therefore, all three countries are collectivist cultures, with similar Hofstedian profiles, and representative of their local regions. In turn, they provide useful and relevant areas for research and potential bridgeheads for DTC advertising into Southern Europe (Greece), the Middle East (United Arab Emirates) and the Far East (Taiwan). The profiles for these three selected markets seem very similar, but of course, they are not identical on all measures. For example Greece records a very high uncertainty avoidance score (112) relative to the United Arab Emirates (68) and Taiwan (69).
Finally, this study addresses a critical research gap and provides an independent, exploratory evaluation of physicians' attitudes to DTC advertising in mainland Europe (Greece), the Middle East (United Arab Emirates) and the Far East (Taiwan).
Across these various representative international markets, this study pursues three main research objectives: to establish physician attitudes towards the value of physician-targeted versus consumer-targeted communications; to assess the level of acceptance, and perceived impacts, of DTC advertising amongst physicians; and to assess physician responses to unbranded disease campaigns.
LITERATURE REVIEW AND HYPOTHESES
Our review of DTC advertising, though comprehensive in nature, is structured to reflect our three main research questions. Most prior research inevitably occurs in the only two branded DTC advertising markets in the world, the United States and New Zealand, though the literature base also has been supplemented by research from the United Kingdom. (We provide a summary of the key physician-based empirical studies of DTC advertising in Appendix II.) For this review, we consider physicians' prior attitudes towards physician-targeted and consumer-targeted communications, preferences for specific types of communications from drug manufacturers, attitudes regarding the ethics and impacts of DTC advertising and attitudes towards unbranded disease awareness campaigns. Petroshius et al. (1995) , who measure the general attitudes of U.S. physicians towards physician-and consumer-targeted communications, find a preference, particularly amongst general practitioners, for the former. Although U.S. medical opinion appeared supportive of the value of DTC advertising in the mid-1990s (Petroshius et al. 1995) , it may have become more negative over time; by 1997, a survey of U.S. family physicians indicated 80 percent of respondents viewed DTC advertising as a poor idea (Kravitz 2000; Mitka 2003 ). An IMS Health survey of 2,300 physicians also showed a 52 percent disapproval rating (Yuan and Duckwitz 2002) . On balance, it appears that in recent years, more U.S. physician surveys have come to oppose than support DTC advertising (Mitka 2003; Thomaselli 2003; Yuan and Duckwitz 2002) .
Physician-versus consumer-targeted communications
The U.K.-based research also has shown a consistent preference for the ethics of physician-targeted rather than consumer-targeted communication (Lowery 2003; Reast and Carson 2000; Reast et al. 2004 Reast et al. , 2008 . These findings mirror the concerns about DTC advertising expressed by the British Medical Association (2001), the professional body that represents physicians in the United Kingdom.
In New Zealand, though the two professional bodies representing physicians have expressed cautious support for the continuation of DTC advertising, grass-roots physician polls (MacKiven 1999) and the top two medical schools (Scrip 2003 Petroshius and colleagues (1995) also indicate that the preferred advertising, that is, directed at physicians rather than consumers, influences the prescribing decisions U.S. physicians make. Research in the United Kingdom (Reast et al. 2004) suggests that physicians prefer types of communication with drug companies that give them the opportunity for dialogue and discussion (Williams and Hensel 1991) .
Previous research therefore implies that detailing or discussions with sales representatives (Soumerai and Avorn 1990) , conversations during clinical meetings, specific drug-related or ailment-related conferences (Evans and Beltramini 1986) or even social events might be preferable to one-way communication with drug manufacturers (Williams and Hensel 1991) . According to the limited amount of extant research available, physicians tend to attribute less value to impersonal information sources, such as physician-targeted advertising (Avorn, Chen and Hartley 1982) , direct mail (Shearer, Gagnon and Eckel 1978) and email campaigns than they do to other forms of more personalised information (Williams and Hensel 1991) . Such preferences for two-way over one-way communications appear to support the 'highquality communications' label often applied to two-way communications (Grunig and Hunt 1984) . As an exception, medical journal articles represent a one-way, impersonal information source, yet prior research (Roberts 1987) indicates that these non-commercial sources tend to be perceived as welcome and valued information sources by physicians.
Therefore, input from research amongst physicians suggests:
Physicians from Greece, the United Arab Emirates and Taiwan significantly prefer two-way rather than one-way (with the exception of journal articles) communications with drug companies.
The impacts of DTC advertising: Value enhancing?
Debates about the impacts of branded DTC advertising generally have centred on impacts on patient-physician relationships, patient behaviours and concerns about communication strategies. First, in terms of the impacts on consumer-physician relationships, Peyrot and colleagues (1998) suggest that consumer awareness of DTC advertising activity may be associated with greater drug knowledge and more discussion with physicians relating to treatment. A U.S. Food and Drug Administration (FDA) survey also shows that increased DTC advertising prompts dialogue between physicians and consumers (Mitka 2003) , which leads to stronger relationships between physicians and consumers (Bonaccorso and Sturchio 2002 ). Yet persons who are highly aware of advertising may not request specific drugs, due to concerns that this would annoy their physician (Peyrot et al. 1998 ). In contrast, Mechanic (1996) , building on prior research by Perri and Nelson (1987) , argues that an increased sense of consumerism in the physician-patient interaction might undermine their relationship. Potential conflicts might emerge in the relationship between physician and consumer, resulting from pressures to prescribe advertised drugs (Foley and Gross 2000; Mintzes et al. 2002; Prince 2003) or patients who may consider switching physicians who deny their drug requests (Kravitz 2000) .
Second, researchers note the impact of DTC advertising on the numbers of consumer requests for medication and visits to the physician (e.g., Reast and Carson 2000) . Are Although some research implies that DTC advertising is educational and informative for consumers (Alperstein and Perrot 1993; Perri and Nelson 1987; Yamey 2001 ), other work indicates that it can result in patient confusion (Foley and Gross 2000) .
Third, U.S. research highlights problems associated with biased, incomplete or misleading advertising (Koerner 1999 ). An FDA survey reveals that 65 percent of physicians believe their patients confuse the relative risks and benefits of drugs that appear in DTC advertising (Aikin et al. 2004) . Also, the U.K. Consumers Association On the basis of literature pertaining to unbranded DTC advertising campaigns, we hypothesise:
Physicians from Greece, the United Arab Emirates and Taiwan are positively disposed towards unbranded disease awareness campaigns.
METHODOLOGY Physician attitude study
This study employs scales from existing, comprehensive survey instruments used in prior DTC advertising research (Reast and Carson 2000; Reast et al. 2004 Reast et al. , 2008 .
These instruments reflect key variables identified by drug communication studies (e.g., Alperstein and Peyrot 1993; Avorn et al. 1982; Petroshius et al. 1995; Shearer et al. 1978; Soumerai and Avorn 1990 Taipei   (capital city) . To complete the self-administered questionnaire, physicians attending two-day regional or national (Taiwan) physician meeting were asked to spend 10-15 minutes and return the questionnaire to the researcher prior to leaving the meeting.
The initial sample was gathered on the first day of each symposium, with a follow-up sample collected from non-responders on the second day. We find no significant differences between responses and thus assert that non-response bias is not a significant concern for this study (Armstrong and Overton 1977) .
A total of 308 physicians (100 in Greece, 105 in the United Arab Emirates and 103 in Taiwan) participated, with an overall response rate of 52 percent across the three markets (see Table 1 ). The samples gathered for each market are comparable to those obtained in U.S. and U.K. physician surveys (Petroshius et al. 1995; Reast and Carson 2000; Reast et al. 2004) . Physicians often are accustomed to receiving incentives for taking part in commercial research, but the academic nature of this study generally prevented requests for such incentives, nor were any provided. The level of physician interest in the subject matter appears to have been a motivator for engaging in the research.
…Place Table 1 about here…
RESULTS AND DISCUSSION
The sample collected, representative of the physician populations for the respective country, reveals the demographic characteristics outlined in Table 2 .
…Place Table 2 
about here…
According to H 1 , physicians from the three countries prefer physician-targeted to patient-targeted marketing communications for prescription drugs. The results in Table 3 confirm that physicians from all regions have a significant preference for physician-targeted relative to consumer-targeted communications (p = .000 for all regions), in support of H 1 .
…Place Table 3 In H 2 , we posited that physicians from the three countries would prefer interactive, two-way communications rather than one-way communication methods (cf. published research articles in journals) from drug companies. The results in Table 4 confirm, at an aggregate level, that physicians from all regions significantly prefer two-way interactive communications over one-way communications (p = .000 for all regions).
…Place Table 4 Although research results published in medical journals are technically a one-way communication format, they prompt favourable responses because they represent more credible and thus valuable information sources (compared with advertising in journals). These articles have been subject to peer review, and they encourage dialogue of sorts through responses to the publishing journal. This result aligns closely with prior research findings pertaining to the usefulness of research articles in journals (Reast et al. 2004; Roberts 1987; Williams and Hensel 1991) , as well as with
We also proposed that physicians from all three countries would be negatively disposed to the ethics and ethics-related impacts of DTC advertising. Consistent with the findings from …Place Table 5 
We also consider the ethics-related impacts of DTC advertising and here find largely consistent results; Greek physicians again tend to hold more negative attitudes towards DTC advertising, whereas physicians from the United Arab Emirates tend to be much more supportive. All our respondents agree that DTC advertising leads to an increase in unnecessary prescribing, yet Greek physicians ( = 1.95, SD = 1.684) appear significantly more negative than their counterparts (p = .004, p = .000).
Moreover, Greek physicians are significantly more likely to believe that DTC advertising undermines the role of the physician as a health specialist ( = 2.52, SD = 2.027, p = .000) and to disagree with the idea that DTC advertising improves health education ( = 4.92, SD = 2.160, p = .000 and .004).
Greek physicians, along with Taiwanese physicians, hold significantly stronger attitudes than their United Arab Emirates counterparts about the pressure that DTC advertising places on physicians to defend their decisions. Greek physicians also feel significantly more strongly that DTC advertising is unlikely to enhance consumerphysician relationships ( = 4.97, SD = 2.042, p = .000 and .002). Interestingly, and perhaps inconsistently, all physicians agreed, and some strongly, that DTC advertising increases unnecessary prescribing, but they also are broadly neutral toward the idea that DTC increases patient visits to the physicians themselves; only Taiwanese physicians ( = 3.67, SD = 1.560) exhibit mild agreement with this statement.
Finally, consistent with the view of the Taiwanese physicians that DTC drives patients to them, these same physicians feel, significantly more strongly than either Greek or United Arab Emirates physicians ( = 3.39, SD = 1.388, p = .017 and .000), that DTC advertising increases the workload for physicians.
The response of Greek physicians is significantly more negative about the likely impacts of DTC advertising than that of Taiwanese or UAE physicians, but it is largely in line with the views described among U.K. physicians (Reast et al. 2004 ).
The only substantive differences relate to perceived increases in consumer traffic and physician workload, about which U.K. physicians are more negative. The results gained from physicians from the United Arab Emirates and Taiwan have no regional comparisons; we address them in greater depth in the conclusion.
Finally, H 4 states that physicians from all three countries should have a positive attitude towards the perceived impacts of unbranded disease awareness campaigns.
The results in Table 6 do not confirm this claim, so we cannot offer support for H 4 .
…Place Table 6 
At the aggregate level, with overall mean scores, the response to unbranded disease awareness campaigns can be described at best as neutral. Physicians perceive some mild, potentially positive impacts of the campaigns, including increases in patient visits ( = 3.36, SD = 1.610), increases in patient requests for medication ( = 3.72, SD = 1.511), improvements in patient knowledge ( = 3.67, SD = 1.677) and increased numbers of prescriptions for promoted categories ( = 3.72, SD = 1.794).
However, when they respond in the context of other measures, they indicate that such campaigns likely generate unnecessary patient visits ( = 3.62, SD = 1.881), and they are neutral when it comes to whether these campaigns will result in patients' recognition of genuine ailments ( = 3.99, SD = 1.756) or just more confusion ( = 3.92, SD = 1.820). Overall, they do not believe these campaigns will increase their workload though ( = 4.19, SD = 1.785).
The responses from the different groups of physicians reveals no absolutely consistent pattern of results, though broadly speaking, Taiwanese and, to a lesser extent, Greek physicians tend to acknowledge a greater impact (both positive and negative), whereas those from the United Arab Emirates tend to perceive little impact of unbranded disease awareness campaigns. The results broadly match those found for U.K. physicians, though this latter group tends to be slightly more negative in perceiving that unbranded disease awareness campaigns encourage a high level of patient traffic (some unnecessary), more drug requests and greater patient confusion (Lowery 2003; Reast et al. 2004 ).
Although we cannot confirm H 4 for all groups of physicians, responses to the impacts of unbranded disease awareness campaigns appear marginally more positive than those to branded DTC advertising (Table 5) , which again is consistent with previous research published in a U.K. setting (Lowery 2003; Reast et al. 2004 ).
RESEARCH IMPLICATIONS Europe, the Middle East and the Far East
Several implications for researchers, practitioners and public policymakers derive from this study, many of which relate to conflicts over the value creation and delivery associated with drug communication strategies. First, physicians value two-way over one-way physician-targeted communication approaches (Reast et al. 2004; Williams and Hensel 1991 ), yet such approaches tend to be more expensive (e.g., sales rep visits at $250-300 per call), whereas many large drug firms are trying to cut back on their large sales forces. Some current relationship management initiatives also attempt to downgrade 'lower value physicians' and target them with less costly communication contacts or fewer customer touches. Cost reduction efforts tend to mean switching from expensive, face-to-face, two-way contacts to less expensive two-way contacts (e.g., telephony) or one-way contacts such as direct mail or email.
Our research suggests many physicians will be unhappy about this decision, because they perceive the less expensive contacts as less valuable and poorer quality. There is thus a clear conflict of interests: Manufacturers derive more value from the exchange (profitability) by switching to cheaper communications formats, but physicians perceive a loss of (informational and relationship) value with this policy.
Second, with regard to DTC advertising and practitioners in the advertising industry, our research indicates the need to acknowledge the nature of the stakeholder environment within the global drug market, if manufacturers hope to work to change the communications policy framework. Following an approach that maximises manufacturer value (e.g., sales, profits, share price) and focuses on end-customer value (e.g., health education, dialogue with physicians, illness recognition), at the expense of the healthcare intermediary, may be short-sighted. Physicians represent an important and influential stakeholder group, and their prescribing decisions have important influences on drug company profits (Dimopoulou and Fill 2000) . Greek physicians-and European physicians in general, it would appear-exhibit very negative attitudes towards both the concept and perceived value and impacts of DTC Working with, rather than against, physicians, should help ensure that the campaigns adopt precise and appropriate targeting, offer improvements in consumer health education and illness recognition and produce few complaints about biased or misleading advertising copy. Such an approach also may encourage physicians and public policymakers to look more favourably on the policy.
Fourth, physicians universally indicate their belief that DTC advertising will lead to an increase in unnecessary prescriptions; therefore, public policymakers should recognise the potential impacts on national drug budgets (Prince 2003) . Regardless of whether DTC advertising drives beneficial visits to the physician or unnecessary wastes of time, the outcome is likely to be increased costs for managing patients and the extra prescriptions generated. Policymakers should weigh the value of DTC advertising in terms of the increased awareness and treatment of genuine illness (particularly among men) against the costs of such as policy.
The U.S. direct-to-consumer advertising market
The advertising industry, especially in the United States, can play a role in calming the fears of key stakeholder groups. Many major, global advertising agencies enjoy a strong position that enables them to recognise the wider geographic policy implications of aggressive advertising strategies in current DTC advertising markets.
It is in the interest of these agencies to guide clients towards more responsible communication strategies, with the knowledge that this approach should lead to at least partial geographic extension of DTC advertising.
The research findings also suggest some specific guidance for the U.S. domestic market situation. For example, many drug companies have chosen a pull strategy and DTC advertising, yet the physician remains a critically important stakeholder for prescription sales (i.e., push strategy). In the end, it is the physician who decides to prescribe a particular drug. Because of the importance of this relationship, and given the widespread evidence of biased, incomplete or misleading U.S. advertising targeted at consumers, physician research panels should be integrated into the communication planning process for new campaigns. This approach could ensure that health educational value exists in the campaigns whilst simultaneously reducing any misleading or confusing advertising and concerns about the 'medicalisation' of trivial diseases. In addition, advertising practitioners should revisit consumer-based positioning and pre-test research that underpins their existing campaigns to confirm they offer clarity and educational value, particularly for older consumers (Foley and Gross 2000) , who are often heavy users of medication.
CONCLUSIONS
Partially because of the conflicts regarding the value being created and delivered to stakeholders in drug markets worldwide, many objections still remain to DTC advertising. Manufacturers appear to have put their own self-interest (i.e., sales and profitability) ahead of delivering value to consumers (healthcare knowledge), at the expense of physicians' interests and value. Many physicians believe that DTC advertising is of dubious value to consumers who might be confused more than educated, to governments that must confront vastly increasing health budgets and to physicians whose relationships with manufacturers suffers and whose value and position gets undermined with consumers. If manufacturers want greater success from their DTC advertising expansion, they should work more closely with their partners (physicians) in the value delivery process they provide to consumers. If physicians feel undermined, pressured and threatened by DTC advertising, they are more likely to oppose its extension.
Physicians from Greece, the United Arab Emirates and Taiwan generally support the ethics of physician-targeted communications relative to consumer-targeted communications, and they exhibit a consistent preference for the value of a two-way interactive approach. Greek physicians are strongly opposed to the ethics, introduction and likely value of DTC advertising. In stark contrast, physicians in Taiwan Greek samples suggests that qualitative research with European physicians should attempt to understand their motivations and objections in more depth, as well as how these concerns might be addressed. .000
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